A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

Fecha de publicación: 3 de noviembre de 2026, 9:35

Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.